NANOG and cancer: Furthermore, NANOG may be clinically relevant in monitoring patients treated with a CSC inhibitor, such as Napabucasin (BBI608), whose strong anti-CSC effect has already been demonstrated in vitro and in vivo in a broad range of cancer types [46].